ClinicalTrials.gg
CompletedNCT03410992BE READYUpdated Apr 15, 2026Results posted

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

A Phase 3 interventional study of Bimekizumab and Placebo in Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis and Psoriatic Arthritis, sponsored by UCB Biopharma SRL. Completed at 77 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
435
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing bimekizumab in Arthritis, Psoriatic — 2 open to participants now, 3 under way, 1 of them phase 3. bimekizumab · Arthritis, Psoriatic.

Enrollment
5th of 14
435 · median 210
Started
2018
the only one that year
Phase 3
8 of 14
none open now
Registered
5th of 14
by date
Lead sponsor
10 of 14
UCB Biopharma SRL

Among the 14 studies testing bimekizumab in Arthritis, Psoriatic, this one is the 5th largest by enrollment, is the only one that started in 2018, is one of 8 in phase 3, and was the 5th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

2 of the 14 studies testing bimekizumab in Arthritis, Psoriatic are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About bimekizumab

bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing bimekizumab in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

Phase 3 study to compare the efficacy of bimekizumab versus placebo in the treatment of subjects with moderate to severe chronic plaque psoriasis.

03

Conditions studied

  • Chronic Plaque Psoriasis
  • Moderate to Severe Chronic Plaque Psoriasis
  • Psoriatic Arthritis

Keywords

  • Bimekizumab
  • PSO
  • Psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be at least 18 years of age
  • Chronic plaque psoriasis (PSO) for at least 6 months prior to the Screening Visit
  • Psoriasis Area Severity Index (PASI) >=12 and body surface area (BSA) affected by PSO >=10% and Investigator's Global Assessment (IGA) score >=3 on a 5-point scale
  • Subject is a candidate for systemic PSO therapy and/or phototherapy
  • Female subject of child bearing potential must be willing to use highly effective method of

Exclusion criteria

Exclusion Criteria:

  • Subject has an active infection (except common cold), a recent serious infection, or a history of opportunistic, recurrent, or chronic infections
  • Subject has concurrent acute or chronic viral or C or (HIV) infection
  • Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection
  • Subject has any other condition, including medical or psychiatric, which, in the Investigator's judgment, would make the subject unsuitable for inclusion in the study
  • Presence of active suicidal ideation or positive suicide behavior
  • Presence of moderately severe major depression or severe major depression
  • Subject has any active or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
435 participants (actual)

Study arms

  • Experimental
    Bimekizumab cohort

    Subjects will receive bimekizumab for 16 Weeks. Subjects who achieve certain predefined response criteria will be re-randomized to either receive bimekizumab or placebo until Week 56. Subjects who do not achieve predefined response criteria will enter the bimekizumab escape arm.

    Drug: Bimekizumab · Other: Placebo

  • Placebo comparator
    Placebo

    Subjects will receive placebo for 16 Weeks. Subjects who achieve certain predefined response criteria will proceed with placebo until Week 56. Subjects who do not achieve certain predefined response criteria will enter the bimekizumab escape arm.

    Other: Placebo

  • Experimental
    Bimekizumab Escape arm

    Subjects who do not achieve certain predefined response criteria at Week 16 or later will enter the bimekizumab escape arm and will receive open-label bimekizumab for 12 weeks.

    Drug: Bimekizumab

Interventions

  • Bimekizumab will be provided at pre-specified time intervals.

    Also known as: UCB4940

  • OtherPlacebo

    Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16

    A PASI90 responder was defined as a participant that achieved 90% reduction from Baseline in the PASI score. Body divided into 4 areas: head/arms/trunk to groin/legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear)-4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0-6 scale. Final PASI=average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The min possible PASI score is 0=no disease, the max score is 72=maximal disease. Study participants with missing score at Week 16 were counted as nonresponders (NRI).

    Time frame: At Week 16

  2. Percentage of Participants With an Investigator's Global Assessment (IGA) Response at Week 16

    The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-Inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response was defined as Clear or Almost Clear with at least a 2-category improvement relative to Baseline. Study participants with missing score at Week 16 were counted as nonresponders (NRI).

    Time frame: At Week 16

Secondary outcomes

  1. Percentage of Participants With a PASI100 Response at Week 16

    A PASI100 responder was defined as a participant that achieved 100% reduction from Baseline in the PASI score. Body divided into 4 areas: head/arms/trunk to groin/legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear)-4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0-6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The min possible PASI score is 0=no disease, the max score is 72=maximal disease. Study participants with missing score at Week 16 were counted as nonresponders (NRI).

    Time frame: At Week 16

  2. Percentage of Participants With a IGA Clear Response at Week 16

    The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response was defined as Clear with at least \>= 2 category improvement relative to Baseline. Study participants with missing score at Week 16 were counted as nonresponders (NRI).

    Time frame: At Week 16

  3. Percentage of Participants With a PASI75 Response at Week 4

    A PASI75 responder was defined as a participant that achieved 75% reduction from Baseline in the PASI score. Body divided into 4 areas: head/arms/trunk to groin/legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear)-4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0-6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The min possible PASI score is 0=no disease, the max score is 72=maximal disease. Study participants with missing score at a given week were counted as nonresponders.

    Time frame: At Week 4

  4. Percentage of Participants With a Patient Symptom Diary Response for Pain at Week 16

    As PRO measure, the PSD (further published as P-SIM) was used to assess key symptoms relevant to patients with moderate to severe plaque psoriasis. Site staff trained participants on the use of the electronic device used to collect ePRO diary data at Screening, device was then dispensed to the participant for home use until Week 16 Visit. The ePRO diary was completed on daily basis from Screening to Week 16 Visit. PSD pain item was assessed daily on a numeric rating scale (NRS) from 0 (no pain) to 10 (very severe pain). PSD score for pain at a given visit was an average of daily values over the week prior to the visit. The response was defined as an improvement (decrease) in pain score higher than the prespecified 1.98 response threshold at Week 16. The endpoint was characterized as percentage of participants with PSD pain response.

    Time frame: At Week 16

  5. Percentage of Participants With a Patient Symptom Diary Response for Itch at Week 16

    A PRO measure, the PSD (further published as P-SIM) was used to assess key symptoms relevant to patients with moderate to severe plaque psoriasis. Site staff trained participants on the use of the electronic device used to collect ePRO diary data at Screening, device was then dispensed to participant for home use until Week 16 Visit. The ePRO diary was completed on daily basis from Screening to Week 16 Visit. PSD itch item was assessed daily on a NRS from 0 (no itch) to 10 (very severe itch). PSD score for itch was an average of daily values over the week prior to the visit. The response was defined as an improvement (decrease) in itch score higher than the prespecified 2.39 response threshold at Week 16. The endpoint was characterized as percentage of participants with a PSD itch response.

    Time frame: At Week 16

  6. Percentage of Participants With a Patient Symptom Diary Response for Scaling at Week 16

    As PRO measure, the PSD (further published as P-SIM) was used to assess key symptoms relevant to patients with moderate to severe plaque psoriasis. Site staff trained participants on the use of the electronic device used to collect ePRO diary data at Screening, device was then dispensed to the participant for home use until Week 16 Visit. The ePRO diary was completed on daily basis from Screening to Week 16 Visit. PSD scaling item was assessed daily on a NRS from 0 (no scaling) to 10 (very severe scaling). PSD score for scaling was an average of daily values over the week prior to the visit. The response was defined as an improvement (decrease) in scaling score higher than the prespecified 2.86 response threshold at Week 16. The endpoint was characterized as percentage of participants with a PSD scaling response.

    Time frame: At Week 16

  7. Percentage of Participants With Scalp IGA Response (Clear or Almost Clear) at Week 16 for Participants With Scalp Psoriasis (PSO) at Baseline

    Only participants with scalp involvement at Baseline completed the scalp IGA. Participants with scalp involvement at Baseline were defined as those with a scalp IGA score \>0 at Baseline. Scalp lesions were assessed in terms of clinical signs of redness, thickness, and scaliness using a 5-point scale (0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, 4= Severe). Scalp IGA 0/1 response at Week 16 was defined as clear (0) or almost clear (1) with at least a 2-category improvement from Baseline to Week 16.

    Time frame: At Week 16

  8. Percentage of Participants With a PASI90 Response at Week 56 Among Week 16 PASI90 Responders

    A PASI90 responder was defined as a participant that achieved 90% reduction from Baseline in the PASI score. Study participants with missing score at Week 56 or who met the criterion for relapse were counted as nonresponders (NRI).

    Time frame: At Week 56

  9. Number of Treatment-emergent Adverse Events (TEAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Initial Treatment Period

    The number of TEAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the adverse event (AE) being considered. If a participant had no events, the total time at risk was used.

    Time frame: From Baseline to end of Initial Treatment Period (up to Week 16)

  10. Number of Serious Adverse Events (SAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Initial Treatment Period

    The number of SAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

    Time frame: From Baseline to end of Initial Treatment Period (up to Week 16)

  11. Number of TEAEs Leading to Withdrawal Adjusted by Duration of Participant Exposure to Study Treatment During the Initial Treatment Period

    The number of TEAEs leading to discontinuation adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

    Time frame: From Baseline to end of Initial Treatment Period (up to Week 16)

  12. Number of Treatment-emergent Adverse Events (TEAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Randomized-Withdrawal Period

    The number of TEAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the adverse event (AE) being considered. If a participant had no events, the total time at risk was used.

    Time frame: From end of Initial Treatment Period (Week 16) until the Safety Follow-Up (up to 56 weeks duration)

  13. Number of Serious Adverse Events (SAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Randomized-Withdrawal Period

    The number of SAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

    Time frame: From end of Initial Treatment Period (Week 16) until the Safety Follow-Up (up to 56 weeks duration)

  14. Number of TEAEs Leading to Withdrawal Adjusted by Duration of Participant Exposure to Study Treatment During the Randomized-Withdrawal Period

    The number of TEAEs leading to discontinuation adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

    Time frame: From end of Initial Treatment Period (Week 16) until the Safety Follow-Up (up to 56 weeks duration)

  15. Number of Treatment-emergent Adverse Events (TEAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Escape Treatment

    The number of TEAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the adverse event (AE) being considered. If a participant had no events, the total time at risk was used.

    Time frame: From Escape Baseline (Week 0) until Safety Follow-Up (up to 28 weeks duration)

  16. Number of Serious Adverse Events (SAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Escape Treatment

    The number of SAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

    Time frame: From Escape Baseline (Week 0) until Safety Follow-Up (up to 28 weeks duration)

  17. Number of TEAEs Leading to Withdrawal Adjusted by Duration of Participant Exposure to Study Treatment During the Escape Treatment

    The number of TEAEs leading to discontinuation adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

    Time frame: From Escape Baseline (Week 0) until Safety Follow-Up (up to 28 weeks duration)

07

Results

Posted Mar 4, 2022

Participant flow

The study started to enroll patients in February 2018 and concluded in January 2020.

Initial Treatment Period: up to Wk16
Participant flow — Initial Treatment Period: up to Wk16
MilestonePlaceboBimekizumab 320 mg Q4WPlacebo/PlaceboBimekizumab 320 mg Q4W/PlaceboBimekizumab 320 mg Q4W/Q8WBimekizumab 320 mg Q4W/Q4WPlacebo EscapeBimekizumab 320 mg Q4W EscapeBimekizumab 320 mg Q4W/ Placebo EscapeBimekizumab 320 mg Q4W/Q8W EscapeBimekizumab 320 mg Q4W/Q4W Escape
Started86349000000000
Completed82340000000000
Not completed49000000000
Withdrew: Adverse event05000000000
Withdrew: Lack of efficacy21000000000
Withdrew: Lost to follow-up13000000000
Withdrew: Withdrawal by subject10000000000
Week 16 Assessment
Participant flow — Week 16 Assessment
MilestonePlaceboBimekizumab 320 mg Q4WPlacebo/PlaceboBimekizumab 320 mg Q4W/PlaceboBimekizumab 320 mg Q4W/Q8WBimekizumab 320 mg Q4W/Q4WPlacebo EscapeBimekizumab 320 mg Q4W EscapeBimekizumab 320 mg Q4W/ Placebo EscapeBimekizumab 320 mg Q4W/Q8W EscapeBimekizumab 320 mg Q4W/Q4W Escape
Started82340000000000
Received escape treatment8123000000000
Completed1311000000000
Not completed8129000000000
Withdrew: Pasi90 non-response at week 168123000000000
Withdrew: Incorrect escapers06000000000
Randomized-Withdrawal Period: up to Wk56
Participant flow — Randomized-Withdrawal Period: up to Wk56
MilestonePlaceboBimekizumab 320 mg Q4WPlacebo/PlaceboBimekizumab 320 mg Q4W/PlaceboBimekizumab 320 mg Q4W/Q8WBimekizumab 320 mg Q4W/Q4WPlacebo EscapeBimekizumab 320 mg Q4W EscapeBimekizumab 320 mg Q4W/ Placebo EscapeBimekizumab 320 mg Q4W/Q8W EscapeBimekizumab 320 mg Q4W/Q4W Escape
Started00110510010600000
Received escape treatment000674700000
Completed00133939400000
Not completed0007271200000
Withdrew: Adverse event00032000000
Withdrew: Lost to follow-up00021200000
Withdrew: Withdrawal by subject00000300000
Withdrew: Relapse at week 20 or later000674700000
Escape Treatment: 12 Weeks
Participant flow — Escape Treatment: 12 Weeks
MilestonePlaceboBimekizumab 320 mg Q4WPlacebo/PlaceboBimekizumab 320 mg Q4W/PlaceboBimekizumab 320 mg Q4W/Q8WBimekizumab 320 mg Q4W/Q4WPlacebo EscapeBimekizumab 320 mg Q4W EscapeBimekizumab 320 mg Q4W/ Placebo EscapeBimekizumab 320 mg Q4W/Q8W EscapeBimekizumab 320 mg Q4W/Q4W Escape
Started00000081236747
Completed00000081226647
Not completed00000001100
Withdrew: Adverse event00000001000
Withdrew: Withdrawal by subject00000000100

Outcome measures

PrimaryPercentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16

A PASI90 responder was defined as a participant that achieved 90% reduction from Baseline in the PASI score. Body divided into 4 areas: head/arms/trunk to groin/legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear)-4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0-6 scale. Final PASI=average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The min possible PASI score is 0=no disease, the max score is 72=maximal disease. Study participants with missing score at Week 16 were counted as nonresponders (NRI).

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16
percentage of participantsPlacebo (RS)Bimekizumab 320 mg Q4W (RS)
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 161.290.8
Statistical analysis
  • Placebo (RS) vs Bimekizumab 320 mg Q4W (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups were based on the CMH test from the general association.) · Odds ratio (or): 496.318 · 95% CI 82.798 to 2975.086
PrimaryPercentage of Participants With an Investigator's Global Assessment (IGA) Response at Week 16

The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-Inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response was defined as Clear or Almost Clear with at least a 2-category improvement relative to Baseline. Study participants with missing score at Week 16 were counted as nonresponders (NRI).

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an Investigator's Global Assessment (IGA) Response at Week 16
percentage of participantsPlacebo (RS)Bimekizumab 320 mg Q4W (RS)
Percentage of Participants With an Investigator's Global Assessment (IGA) Response at Week 161.292.6
Statistical analysis
  • Placebo (RS) vs Bimekizumab 320 mg Q4W (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups were based on the CMH test from the general association.) · Odds ratio (or): 657.255 · 95% CI 105.792 to 4083.333
SecondaryPercentage of Participants With a PASI100 Response at Week 16

A PASI100 responder was defined as a participant that achieved 100% reduction from Baseline in the PASI score. Body divided into 4 areas: head/arms/trunk to groin/legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear)-4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0-6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The min possible PASI score is 0=no disease, the max score is 72=maximal disease. Study participants with missing score at Week 16 were counted as nonresponders (NRI).

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a PASI100 Response at Week 16
percentage of participantsPlacebo (RS)Bimekizumab 320 mg Q4W (RS)
Percentage of Participants With a PASI100 Response at Week 161.268.2
Statistical analysis
  • Placebo (RS) vs Bimekizumab 320 mg Q4W (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups were based on the CMH test from the general association.) · Odds ratio (or): 220.038 · 95% CI 28.757 to 1683.639
SecondaryPercentage of Participants With a IGA Clear Response at Week 16

The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response was defined as Clear with at least \>= 2 category improvement relative to Baseline. Study participants with missing score at Week 16 were counted as nonresponders (NRI).

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a IGA Clear Response at Week 16
percentage of participantsPlacebo (RS)Bimekizumab 320 mg Q4W (RS)
Percentage of Participants With a IGA Clear Response at Week 161.269.6
Statistical analysis
  • Placebo (RS) vs Bimekizumab 320 mg Q4W (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups were based on the CMH test from the general association.) · Odds ratio (or): 224.744 · 95% CI 30.130 to 1676.425
SecondaryPercentage of Participants With a PASI75 Response at Week 4

A PASI75 responder was defined as a participant that achieved 75% reduction from Baseline in the PASI score. Body divided into 4 areas: head/arms/trunk to groin/legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear)-4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0-6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The min possible PASI score is 0=no disease, the max score is 72=maximal disease. Study participants with missing score at a given week were counted as nonresponders.

Time frame:
At Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With a PASI75 Response at Week 4
percentage of participantsPlacebo (RS)Bimekizumab 320 mg Q4W (RS)
Percentage of Participants With a PASI75 Response at Week 41.275.9
Statistical analysis
  • Placebo (RS) vs Bimekizumab 320 mg Q4W (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups were based on the CMH test from the general association.) · Odds ratio (or): 316.641 · 95% CI 39.423 to 2543.254
SecondaryPercentage of Participants With a Patient Symptom Diary Response for Pain at Week 16

As PRO measure, the PSD (further published as P-SIM) was used to assess key symptoms relevant to patients with moderate to severe plaque psoriasis. Site staff trained participants on the use of the electronic device used to collect ePRO diary data at Screening, device was then dispensed to the participant for home use until Week 16 Visit. The ePRO diary was completed on daily basis from Screening to Week 16 Visit. PSD pain item was assessed daily on a numeric rating scale (NRS) from 0 (no pain) to 10 (very severe pain). PSD score for pain at a given visit was an average of daily values over the week prior to the visit. The response was defined as an improvement (decrease) in pain score higher than the prespecified 1.98 response threshold at Week 16. The endpoint was characterized as percentage of participants with PSD pain response.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Patient Symptom Diary Response for Pain at Week 16
percentage of participantsPlacebo (RS)Bimekizumab 320 mg Q4W (RS)
Percentage of Participants With a Patient Symptom Diary Response for Pain at Week 169.078.8
Statistical analysis
  • Placebo (RS) vs Bimekizumab 320 mg Q4W (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups were based on the CMH test from the general association.) · Odds ratio (or): 34.325 · 95% CI 14.220 to 82.856
SecondaryPercentage of Participants With a Patient Symptom Diary Response for Itch at Week 16

A PRO measure, the PSD (further published as P-SIM) was used to assess key symptoms relevant to patients with moderate to severe plaque psoriasis. Site staff trained participants on the use of the electronic device used to collect ePRO diary data at Screening, device was then dispensed to participant for home use until Week 16 Visit. The ePRO diary was completed on daily basis from Screening to Week 16 Visit. PSD itch item was assessed daily on a NRS from 0 (no itch) to 10 (very severe itch). PSD score for itch was an average of daily values over the week prior to the visit. The response was defined as an improvement (decrease) in itch score higher than the prespecified 2.39 response threshold at Week 16. The endpoint was characterized as percentage of participants with a PSD itch response.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Patient Symptom Diary Response for Itch at Week 16
percentage of participantsPlacebo (RS)Bimekizumab 320 mg Q4W (RS)
Percentage of Participants With a Patient Symptom Diary Response for Itch at Week 165.675.5
Statistical analysis
  • Placebo (RS) vs Bimekizumab 320 mg Q4W (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups were based on the CMH test from the general association.) · Odds ratio (or): 43.497 · 95% CI 15.728 to 120.295
SecondaryPercentage of Participants With a Patient Symptom Diary Response for Scaling at Week 16

As PRO measure, the PSD (further published as P-SIM) was used to assess key symptoms relevant to patients with moderate to severe plaque psoriasis. Site staff trained participants on the use of the electronic device used to collect ePRO diary data at Screening, device was then dispensed to the participant for home use until Week 16 Visit. The ePRO diary was completed on daily basis from Screening to Week 16 Visit. PSD scaling item was assessed daily on a NRS from 0 (no scaling) to 10 (very severe scaling). PSD score for scaling was an average of daily values over the week prior to the visit. The response was defined as an improvement (decrease) in scaling score higher than the prespecified 2.86 response threshold at Week 16. The endpoint was characterized as percentage of participants with a PSD scaling response.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Patient Symptom Diary Response for Scaling at Week 16
percentage of participantsPlacebo (RS)Bimekizumab 320 mg Q4W (RS)
Percentage of Participants With a Patient Symptom Diary Response for Scaling at Week 165.778.0
Statistical analysis
  • Placebo (RS) vs Bimekizumab 320 mg Q4W (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups were based on the CMH test from the general association.) · Odds ratio (or): 60.946 · 95% CI 20.560 to 180.669
SecondaryPercentage of Participants With Scalp IGA Response (Clear or Almost Clear) at Week 16 for Participants With Scalp Psoriasis (PSO) at Baseline

Only participants with scalp involvement at Baseline completed the scalp IGA. Participants with scalp involvement at Baseline were defined as those with a scalp IGA score \>0 at Baseline. Scalp lesions were assessed in terms of clinical signs of redness, thickness, and scaliness using a 5-point scale (0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, 4= Severe). Scalp IGA 0/1 response at Week 16 was defined as clear (0) or almost clear (1) with at least a 2-category improvement from Baseline to Week 16.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Scalp IGA Response (Clear or Almost Clear) at Week 16 for Participants With Scalp Psoriasis (PSO) at Baseline
percentage of participantsPlacebo (RS)Bimekizumab 320 mg Q4W (RS)
Percentage of Participants With Scalp IGA Response (Clear or Almost Clear) at Week 16 for Participants With Scalp Psoriasis (PSO) at Baseline6.892.3
Statistical analysis
  • Placebo (RS) vs Bimekizumab 320 mg Q4W (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups were based on the CMH test from the general association.) · Odds ratio (or): 158.000 · 95% CI 49.263 to 506.745
SecondaryPercentage of Participants With a PASI90 Response at Week 56 Among Week 16 PASI90 Responders

A PASI90 responder was defined as a participant that achieved 90% reduction from Baseline in the PASI score. Study participants with missing score at Week 56 or who met the criterion for relapse were counted as nonresponders (NRI).

Time frame:
At Week 56
Reported as:
Number · percentage of participants
Percentage of Participants With a PASI90 Response at Week 56 Among Week 16 PASI90 Responders
percentage of participantsBimekizumab 320 mg Q4W/Placebo (WK16ResS)Bimekizumab 320 mg Q4W/Q8W (WK16ResS)Bimekizumab 320 mg Q4W/Q4W (WK16ResS)Bimekizumab 320 mg Q4W/Q8W+Q4W/Q4W (WK16ResS)
Percentage of Participants With a PASI90 Response at Week 56 Among Week 16 PASI90 Responders16.291.086.888.8
Statistical analysis
  • Bimekizumab 320 mg Q4W/Placebo (WK16ResS) vs Bimekizumab 320 mg Q4W/Q8W (WK16ResS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups were based on the CMH test from the general association.) · Odds ratio (or): 45.192 · 95% CI 18.622 to 109.672
  • Bimekizumab 320 mg Q4W/Placebo (WK16ResS) vs Bimekizumab 320 mg Q4W/Q4W (WK16ResS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups were based on the CMH test from the general association.) · Odds ratio (or): 49.297 · 95% CI 18.887 to 128.673
  • Bimekizumab 320 mg Q4W/Placebo (WK16ResS) vs Bimekizumab 320 mg Q4W/Q8W+Q4W/Q4W (WK16ResS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups were based on the CMH test from the general association.) · Odds ratio (or): 47.406 · 95% CI 22.087 to 101.750
SecondaryNumber of Treatment-emergent Adverse Events (TEAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Initial Treatment Period

The number of TEAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the adverse event (AE) being considered. If a participant had no events, the total time at risk was used.

Time frame:
From Baseline to end of Initial Treatment Period (up to Week 16)
Reported as:
Number · no. of new events per 100 subject-years
Number of Treatment-emergent Adverse Events (TEAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Initial Treatment Period
no. of new events per 100 subject-yearsPlacebo (SS)Bimekizumab 320 mg Q4W (SS)
Number of Treatment-emergent Adverse Events (TEAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Initial Treatment Period177.38 (123.55 to 246.69)323.61 (281.60 to 370.11)
SecondaryNumber of Serious Adverse Events (SAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Initial Treatment Period

The number of SAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

Time frame:
From Baseline to end of Initial Treatment Period (up to Week 16)
Reported as:
Number · no. of new events per 100 subject-years
Number of Serious Adverse Events (SAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Initial Treatment Period
no. of new events per 100 subject-yearsPlacebo (SS)Bimekizumab 320 mg Q4W (SS)
Number of Serious Adverse Events (SAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Initial Treatment Period7.66 (0.93 to 27.68)5.59 (2.05 to 12.17)
SecondaryNumber of TEAEs Leading to Withdrawal Adjusted by Duration of Participant Exposure to Study Treatment During the Initial Treatment Period

The number of TEAEs leading to discontinuation adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

Time frame:
From Baseline to end of Initial Treatment Period (up to Week 16)
Reported as:
Number · no. of new events per 100 subject-years
Number of TEAEs Leading to Withdrawal Adjusted by Duration of Participant Exposure to Study Treatment During the Initial Treatment Period
no. of new events per 100 subject-yearsPlacebo (SS)Bimekizumab 320 mg Q4W (SS)
Number of TEAEs Leading to Withdrawal Adjusted by Duration of Participant Exposure to Study Treatment During the Initial Treatment Period0 (NA to NA)2.78 (0.57 to 8.12)
SecondaryNumber of Treatment-emergent Adverse Events (TEAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Randomized-Withdrawal Period

The number of TEAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the adverse event (AE) being considered. If a participant had no events, the total time at risk was used.

Time frame:
From end of Initial Treatment Period (Week 16) until the Safety Follow-Up (up to 56 weeks duration)
Reported as:
Number · no. of new events per 100 subject-years
Number of Treatment-emergent Adverse Events (TEAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Randomized-Withdrawal Period
no. of new events per 100 subject-yearsPlacebo/Placebo (WK16ResS)Bimekizumab 320 mg Q4W/Placebo (WK16ResS)Bimekizumab 320 mg Q4W/Q8W (WK16ResS)Bimekizumab 320 mg Q4W/Q4W (WK16ResS)
Number of Treatment-emergent Adverse Events (TEAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Randomized-Withdrawal Period144.37 (3.66 to 804.36)242.11 (189.44 to 304.90)224.87 (177.46 to 281.05)208.88 (165.11 to 260.69)
SecondaryNumber of Serious Adverse Events (SAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Randomized-Withdrawal Period

The number of SAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

Time frame:
From end of Initial Treatment Period (Week 16) until the Safety Follow-Up (up to 56 weeks duration)
Reported as:
Number · no. of new events per 100 subject-years
Number of Serious Adverse Events (SAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Randomized-Withdrawal Period
no. of new events per 100 subject-yearsPlacebo/Placebo (WK16ResS)Bimekizumab 320 mg Q4W/Placebo (WK16ResS)Bimekizumab 320 mg Q4W/Q8W (WK16ResS)Bimekizumab 320 mg Q4W/Q4W (WK16ResS)
Number of Serious Adverse Events (SAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Randomized-Withdrawal Period0 (NA to NA)7.20 (1.96 to 18.43)4.04 (0.83 to 11.80)6.64 (2.16 to 15.50)
SecondaryNumber of TEAEs Leading to Withdrawal Adjusted by Duration of Participant Exposure to Study Treatment During the Randomized-Withdrawal Period

The number of TEAEs leading to discontinuation adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

Time frame:
From end of Initial Treatment Period (Week 16) until the Safety Follow-Up (up to 56 weeks duration)
Reported as:
Number · no. of new events per 100 subject-years
Number of TEAEs Leading to Withdrawal Adjusted by Duration of Participant Exposure to Study Treatment During the Randomized-Withdrawal Period
no. of new events per 100 subject-yearsPlacebo/Placebo (WK16ResS)Bimekizumab 320 mg Q4W/Placebo (WK16ResS)Bimekizumab 320 mg Q4W/Q8W (WK16ResS)Bimekizumab 320 mg Q4W/Q4W (WK16ResS)
Number of TEAEs Leading to Withdrawal Adjusted by Duration of Participant Exposure to Study Treatment During the Randomized-Withdrawal Period0 (NA to NA)5.33 (1.10 to 15.58)2.69 (0.33 to 9.71)0 (NA to NA)
SecondaryNumber of Treatment-emergent Adverse Events (TEAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Escape Treatment

The number of TEAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the adverse event (AE) being considered. If a participant had no events, the total time at risk was used.

Time frame:
From Escape Baseline (Week 0) until Safety Follow-Up (up to 28 weeks duration)
Reported as:
Number · no. of new events per 100 subject-years
Number of Treatment-emergent Adverse Events (TEAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Escape Treatment
no. of new events per 100 subject-yearsPlacebo Escape (ESS)Bimekizumab 320 mg Q4W Escape (ESS)Bimekizumab 320 mg Q4W/ Placebo Escape (ESS)Bimekizumab 320 mg Q4W/Q8W Escape (ESS)Bimekizumab 320 mg Q4W/Q4W Escape (ESS)
Number of Treatment-emergent Adverse Events (TEAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Escape Treatment235.86 (164.29 to 328.03)287.19 (143.36 to 513.86)180.89 (115.90 to 269.15)491.37 (101.33 to 1435.98)349.52 (95.23 to 894.91)
SecondaryNumber of Serious Adverse Events (SAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Escape Treatment

The number of SAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

Time frame:
From Escape Baseline (Week 0) until Safety Follow-Up (up to 28 weeks duration)
Reported as:
Number · no. of new events per 100 subject-years
Number of Serious Adverse Events (SAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Escape Treatment
no. of new events per 100 subject-yearsPlacebo Escape (ESS)Bimekizumab 320 mg Q4W Escape (ESS)Bimekizumab 320 mg Q4W/ Placebo Escape (ESS)Bimekizumab 320 mg Q4W/Q8W Escape (ESS)Bimekizumab 320 mg Q4W/Q4W Escape (ESS)
Number of Serious Adverse Events (SAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Escape Treatment5.24 (0.13 to 29.22)0 (NA to NA)0 (NA to NA)0 (NA to NA)0 (NA to NA)
SecondaryNumber of TEAEs Leading to Withdrawal Adjusted by Duration of Participant Exposure to Study Treatment During the Escape Treatment

The number of TEAEs leading to discontinuation adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

Time frame:
From Escape Baseline (Week 0) until Safety Follow-Up (up to 28 weeks duration)
Reported as:
Number · no. of new events per 100 subject-years
Number of TEAEs Leading to Withdrawal Adjusted by Duration of Participant Exposure to Study Treatment During the Escape Treatment
no. of new events per 100 subject-yearsPlacebo Escape (ESS)Bimekizumab 320 mg Q4W Escape (ESS)Bimekizumab 320 mg Q4W/ Placebo Escape (ESS)Bimekizumab 320 mg Q4W/Q8W Escape (ESS)Bimekizumab 320 mg Q4W/Q4W Escape (ESS)
Number of TEAEs Leading to Withdrawal Adjusted by Duration of Participant Exposure to Study Treatment During the Escape Treatment0 (NA to NA)18.77 (0.48 to 104.58)0 (NA to NA)0 (NA to NA)0 (NA to NA)

Adverse events

Collected over Adverse events were collected from Baseline (Week 0) until Safety Follow-Up Visit (up to 80 weeks duration). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (SS)0/86 (0%)2/86 (2.3%)15/86 (17.4%)
Bimekizumab 320 mg Q4W (SS)0/349 (0%)6/349 (1.7%)66/349 (18.9%)
Placebo/Placebo (WK16ResS)0/1 (0%)0/1 (0%)1/1 (100%)
Bimekizumab 320 mg Q4W/Placebo (WK16ResS)0/105 (0%)4/105 (3.8%)34/105 (32.4%)
Bimekizumab 320 mg Q4W/Q8W (WK16ResS)0/100 (0%)3/100 (3%)40/100 (40%)
Bimekizumab 320 mg Q4W/Q4W (WK16ResS)0/106 (0%)5/106 (4.7%)34/106 (32.1%)
Placebo Escape (ESS)0/81 (0%)1/81 (1.2%)8/81 (9.9%)
Bimekizumab 320 mg Q4W Escape (ESS)0/23 (0%)0/23 (0%)5/23 (21.7%)
Bimekizumab 320 mg Q4W/ Placebo Escape (ESS)0/67 (0%)0/67 (0%)11/67 (16.4%)
Bimekizumab 320 mg Q4W/Q8W Escape (ESS)0/4 (0%)0/4 (0%)3/4 (75%)
Bimekizumab 320 mg Q4W/Q4W Escape (ESS)0/7 (0%)0/7 (0%)4/7 (57.1%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventPlacebo (SS)Bimekizumab 320 mg Q4W (SS)Placebo/Placebo (WK16ResS)Bimekizumab 320 mg Q4W/Placebo (WK16ResS)Bimekizumab 320 mg Q4W/Q8W (WK16ResS)Bimekizumab 320 mg Q4W/Q4W (WK16ResS)Placebo Escape (ESS)Bimekizumab 320 mg Q4W Escape (ESS)Bimekizumab 320 mg Q4W/ Placebo Escape (ESS)Bimekizumab 320 mg Q4W/Q8W Escape (ESS)Bimekizumab 320 mg Q4W/Q4W Escape (ESS)
DiarrhoeaGastrointestinal disorders0/860/3490/10/1052/1000/1060/810/230/670/40/7
Ischaemic cardiomyopathyCardiac disorders0/860/3490/10/1050/1000/1061/810/230/670/40/7
Coronary artery diseaseCardiac disorders0/860/3490/10/1050/1000/1061/810/230/670/40/7
Duodenal ulcer haemorrhageGastrointestinal disorders0/860/3490/10/1050/1000/1061/810/230/670/40/7
Type 2 diabetes mellitusMetabolism and nutrition disorders0/860/3490/10/1050/1000/1061/810/230/670/40/7
SyncopeNervous system disorders0/860/3490/10/1050/1000/1061/810/230/670/40/7
Myocardial infarctionCardiac disorders1/860/3490/10/1050/1000/1060/810/230/670/40/7
Mitral valve prolapseCardiac disorders1/860/3490/10/1050/1000/1060/810/230/670/40/7
Acute myocardial infarctionCardiac disorders0/860/3490/10/1051/1000/1060/810/230/670/40/7
Retinal detachmentEye disorders0/861/3490/11/1050/1000/1060/810/230/670/40/7
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlacebo (SS)Bimekizumab 320 mg Q4W (SS)Placebo/Placebo (WK16ResS)Bimekizumab 320 mg Q4W/Placebo (WK16ResS)Bimekizumab 320 mg Q4W/Q8W (WK16ResS)Bimekizumab 320 mg Q4W/Q4W (WK16ResS)Placebo Escape (ESS)Bimekizumab 320 mg Q4W Escape (ESS)Bimekizumab 320 mg Q4W/ Placebo Escape (ESS)Bimekizumab 320 mg Q4W/Q8W Escape (ESS)Bimekizumab 320 mg Q4W/Q4W Escape (ESS)
Upper respiratory tract infectionInfections and infestations7/8614/3491/15/1058/10012/1063/811/232/670/41/7
Dental cariesGastrointestinal disorders1/860/3490/10/1050/1000/1060/810/230/671/40/7
ImpetigoInfections and infestations1/862/3490/11/1050/1001/1060/810/230/671/40/7
Rib fractureInjury, poisoning and procedural complications0/860/3490/10/1050/1001/1060/810/230/671/40/7
NasopharyngitisInfections and infestations4/8623/3490/120/10523/10011/1061/811/232/670/40/7
NeutropeniaBlood and lymphatic system disorders0/862/3490/10/1051/1000/1060/811/230/670/41/7
Tinea pedisInfections and infestations0/864/3490/10/1050/1001/1060/810/230/670/41/7
Body tineaInfections and infestations0/861/3490/10/1051/1000/1060/810/230/670/41/7
Tinea capitisInfections and infestations0/860/3490/10/1050/1000/1060/810/230/670/41/7
PsoriasisSkin and subcutaneous tissue disorders4/861/3490/13/1050/1001/1060/811/230/670/41/7

Baseline characteristics

Baseline Characteristics refer to the Randomized Set (RS) which consisted of all randomized study participants.

Age, Categorical
Age, Categorical(Participants)PlaceboBimekizumab 320 mg Q4WTotal Title
<=18 years213
Between 18 and 65 years80327407
>=65 years42125
Age, Continuous
Age, Continuous(years)PlaceboBimekizumab 320 mg Q4WTotal Title
Mean43.5 ± 13.144.5 ± 12.944.3 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBimekizumab 320 mg Q4WTotal Title
Female2894122
Male58255313
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboBimekizumab 320 mg Q4WTotal Title
Asian51318
Black066
Native Hawaiian or other Pacific Islander022
White79324403
Other/mixed246
08

Study locations

77 sites
  • Ps0013 919
    San Diego, California 92103, United States
  • Ps0013 955
    San Diego, California 92123, United States
  • Ps0013 967
    Santa Monica, California 90404, United States
  • Ps0013 928
    Fort Myers, Florida 33912, United States
  • Ps0013 966
    Sandy Springs, Georgia 30329, United States
  • Ps0013 954
    Skokie, Illinois 60077, United States
  • Ps0013 962
    Owensboro, Kentucky 42303, United States
  • Ps0013 944
    New Orleans, Louisiana 70115, United States
  • Ps0013 940
    Beverly, Massachusetts 01915, United States
  • Ps0013 901
    Portsmouth, New Hampshire 03801, United States
  • Ps0013 956
    Verona, New Jersey 07044-2946, United States
  • Ps0013 947
    Buffalo, New York 14221, United States
  • Ps0013 968
    New York, New York 10021, United States
  • Ps0013 965
    New York, New York 10025, United States
  • Ps0013 963
    Rochester, New York 14623, United States
  • Ps0013 949
    Cleveland, Ohio 44106-1716, United States
  • Ps0013 929
    Portland, Oregon 97223, United States
  • Ps0013 937
    Johnston, Rhode Island 02919, United States
  • Ps0013 914
    San Antonio, Texas 78213, United States
  • Ps0013 933
    Murray, Utah 84107, United States
  • Ps0013 003
    Carlton, Australia
  • Ps0013 008
    East Melbourne, Australia
  • Ps0013 006
    Kogarah, Australia
  • Ps0013 658
    Ajax, Canada
  • Ps0013 672
    Edmonton, Canada
  • Ps0013 671
    Hamilton, Canada
  • Ps0013 675
    Markham, Canada
  • Ps0013 663
    Mississauga, Canada
  • Ps0013 660
    Montreal, Canada
  • Ps0013 668
    North Bay, Canada
  • Ps0013 667
    Ottawa, Canada
  • Ps0013 665
    Québec, Canada
  • Ps0013 676
    Surrey, Canada
  • Ps0013 657
    Waterloo, Canada
  • Ps0013 202
    Hamburg, Germany
  • Ps0013 220
    Hamburg, Germany
  • Ps0013 219
    Münster, Germany
  • Ps0013 200
    Schwerin, Germany
  • Ps0013 204
    Witten, Germany
  • Ps0013 261
    Budapest, Hungary
  • Ps0013 262
    Miskolc, Hungary
  • Ps0013 253
    Orosháza, Hungary
  • Ps0013 260
    Szeged, Hungary
  • Ps0013 250
    Szolnok, Hungary
  • Ps0013 258
    Veszprém, Hungary
  • Ps0013 355
    Bialystok, Poland
  • Ps0013 361
    Bialystok, Poland
  • Ps0013 369
    Bialystok, Poland
  • Ps0013 352
    Gdansk, Poland
  • Ps0013 358
    Katowice, Poland
  • Ps0013 359
    Katowice, Poland
  • Ps0013 366
    Katowice, Poland
  • Ps0013 357
    Kielce, Poland
  • Ps0013 363
    Krakow, Poland
  • Ps0013 360
    Lodz, Poland
  • Ps0013 356
    Lublin, Poland
  • Ps0013 374
    Poznan, Poland
  • Ps0013 353
    Szczecin, Poland
  • Ps0013 350
    Warsaw, Poland
  • Ps0013 351
    Warsaw, Poland
  • Ps0013 354
    Warsaw, Poland
  • Ps0013 365
    Wroclaw, Poland
  • Ps0013 368
    Wroclaw, Poland
  • Ps0013 370
    Wroclaw, Poland
  • Ps0013 400
    Moscow, Russia
  • Ps0013 402
    Moscow, Russia
  • Ps0013 403
    Moscow, Russia
  • Ps0013 404
    Saint Petersburg, Russia
  • Ps0013 405
    Saint Petersburg, Russia
  • Ps0013 401
    Saratov, Russia
  • Ps0013 406
    Yaroslavl, Russia
  • Ps0013 701
    Busan, South Korea
  • Ps0013 705
    Seongnam-si, South Korea
  • Ps0013 703
    Seoul, South Korea
  • Ps0013 550
    Manchester, United Kingdom
  • Ps0013 554
    Reading, United Kingdom
  • Ps0013 555
    Salford, United Kingdom
09

References and documents

Publications

  • Gordon KB, Langley RG, Warren RB, Okubo Y, Stein Gold L, Merola JF, Peterson L, Wixted K, Cross N, Deherder D, Thaci D. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2022 Jul 1;158(7):735-744. doi: 10.1001/jamadermatol.2022.1185. PubMed 35544084 ↗
  • Gordon KB, Langley RG, Warren RB, Okubo Y, Rosmarin D, Lebwohl M, Peterson L, Madden C, de Cuyper D, Davies O, Thaci D. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials. Br J Dermatol. 2024 Mar 15;190(4):477-485. doi: 10.1093/bjd/ljad429. PubMed 37950894 ↗
  • Strober B, Boehncke WH, Krueger JG, Magnolo N, Vender R, Warren RB, Lopez Pinto JM, Kavanagh S, Hoepken B, Gisondi P. Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials. Dermatol Ther (Heidelb). 2025 Dec;15(12):3633-3650. doi: 10.1007/s13555-025-01557-1. Epub 2025 Oct 8. PubMed 41060492 ↗
  • Armstrong A, Papp KA, Lebwohl M, Savage LJ, Yamanaka K, Vlase DE, Warham R, Lambert J, Lopez Pinto JM, Wixted K, Thaci D. Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT. Dermatol Ther (Heidelb). 2026 Jan;16(1):585-603. doi: 10.1007/s13555-025-01595-9. Epub 2025 Dec 8. PubMed 41359217 ↗
  • Krueger JG, Cutcutache I, Lebwohl M, Gudjonsson JE, Pinter A, Langley RG, Merola J, Tada Y, Skelton A, Rastrick J, Ferecsko AS, Page M, Davies O, Lopez Pinto JM, Warham R, Shaw S, Warren RB. Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durability. J Allergy Clin Immunol. 2026 Apr;157(4):905-916. doi: 10.1016/j.jaci.2025.12.1013. Epub 2026 Jan 22. PubMed 41580158 ↗
  • Gisondi P, Elewski B, Pinter A, Yamaguchi Y, Gooderham M, Kavanagh S, Wixted K, Cross N, Szilagyi B, Merola JF. Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years. J Dermatolog Treat. 2026 Dec;37(1):2637344. doi: 10.1080/09546634.2026.2637344. Epub 2026 Mar 9. PubMed 41800601 ↗
  • Blauvelt A, Langley RG, Lebwohl M, Strober B, Warren RB, Puig L, Morita A, Gordon KB, Fernandez-Penas P, Kavanagh S, Lopez Pinto JM, Lambert J, Hoepken B, Deherder D, Cross N, Thaci D. Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. J Am Acad Dermatol. 2025 Sep;93(3):644-653. doi: 10.1016/j.jaad.2025.04.038. Epub 2025 Apr 24. PubMed 40286813 ↗
  • Merola JF, Gottlieb AB, Pinter A, Elewski B, Gooderham M, Warren RB, Piaserico S, Wixted K, Cross N, Tilt N, Wiegratz S, Mrowietz U. Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials. Dermatol Ther (Heidelb). 2024 Dec;14(12):3291-3306. doi: 10.1007/s13555-024-01295-w. Epub 2024 Nov 22. PubMed 39578348 ↗
  • Warren RB, Gottlieb AB, Merola JF, Garcia L, Cioffi C, Peterson L, Pelligra C, Ciaravino V. Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials. Dermatol Ther (Heidelb). 2021 Oct;11(5):1551-1569. doi: 10.1007/s13555-021-00570-4. Epub 2021 Jul 14. PubMed 34260044 ↗
  • Gordon KB, Foley P, Krueger JG, Pinter A, Reich K, Vender R, Vanvoorden V, Madden C, White K, Cioffi C, Blauvelt A. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021 Feb 6;397(10273):475-486. doi: 10.1016/S0140-6736(21)00126-4. PubMed 33549192 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Dec 2018, 10 months.

Results were first posted in Mar 2022, 3 years 2 months after primary completion. A results delay was requested in Jan 2020.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 10 months is below that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2018
First posted
Jan 25, 2018
StartActual
Feb 5, 2018
Primary completionActual
Dec 28, 2018
CompletionActual
Jan 7, 2020
Results delay requested
Jan 6, 2020
Results first posted
Mar 4, 2022
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03410992
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Jan 25, 2018
Start date
Feb 5, 2018
Primary completion
Dec 28, 2018
Completion
Jan 7, 2020
Results posted
Mar 4, 2022
Last update
Apr 15, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion